—
The U.S. biosimilars market will gain momentum from the increasing government support to adopt biosimilars in the healthcare sectors. According to a report by Fortune Business Insights, titled, “Biosimilars: U.S. Market Analysis, Insights and Forecast, 2019-2026,” the U.S. biosimilars market is projected to reach US$ 17,696.0 Mn by 2026.The report provides valuable insights into the drivers influencing growth of the market. As per the report, the U.S. biosimilars market is anticipated to report an impressive CAGR of 54.7% during the forecast period. The report also states that the U.S. market was valued at US$ 436.1 Mn in 2018.
Browse Complete Report Details@ https://www.fortunebusinessinsights.com/industry-reports/u-s-biosimilars-market-100990
Increased Research and Development Initiatives to Drive the Market
Biosimilars are the copies of original products. Due to the high cost of pharmaceutical drugs, healthcare facilities are not accessible to people from every economical stratum. This is where biosimilars come to recuse. Being an identical copy, biosimilars help in treating chronic diseases like cancer and arthritis in an effective manner just as original medications do.
The market is likely to grow during the forecast period because of an increasing demand from the masses. Also, a rise in research and development initiatives by prominent organizations have increased market opportunities. This has led to tough competition in the U.S. biosimilars market.
By Drug Class
· Filgrastim & Pegfilgrastim
· Monoclonal Antibodies
By Distribution Channel
· Hospital Pharmacy
· Retail Pharmacy
· Online Pharmacy
Autoimmune Diseases Segment Projected to Dominate the Market in the U.S.
The U.S. biosimilars market is classified into three segments, namely, by distribution channel, by disease indication, and by drug class. By distribution channel, the market is grouped into online pharmacy, hospital pharmacy, and retail pharmacy. In terms of disease indication, the market is divided into cancer and autoimmune diseases such as arthritis, neutropenia, psoriasis, and others.
Get Sample PDF Brochure@ https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/u-s-biosimilars-market-100990
Pfizer Inc., Samsung Bioepis Co. Ltd., and Other Key Players Tend to Focus on Product Launch to Strengthen Position
Samsung Bioepis Co. Ltd, a biopharmaceutical company, received approval from Food and Drugs Administrations for ETICOVO, a biosimilar of Etanercept in April 2019. It is used for the treatment of plaque psoriasis, rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, ankylosing spondylitis, and psoriatic arthritis.
Pfizer Inc. a multinational pharmaceutical company based in the U.S., received approval from FDA for TRAZIMERA, a biosimilar referencing Herceptin in March 2019. It will be used to treat gastroesophageal junction adenocarcinoma and breast cancer. Earlier in July 2018, Pfizer Inc. announced that the company has received FDA approval for NIVESTYM. It is a biosimilar to Neupogen that is approved to treat neutropenia.
The FDA also granted approval for Truxima, the first biosimilar of rituximab in November 2018. It is developed by Celltrion Inc., a biopharmaceutical company headquartered in South Korea, for the treatment of non-Hodgkin’s lymphoma.
U.S. BIOSIMILARS MARKET PLAYERS:
-Novartis AG
-Merck & Co.
-Coherus BioSciences, Inc.
-AbbVie Inc.
-Pfizer Inc.
-Hoffmann-La Roche Ltd.
-Eli Lilly and Company
-Teva Pharmaceutical Industries Ltd.
-Celltrion Inc.
-Amgen Inc.
Buy Complete Report@ https://www.fortunebusinessinsights.com/checkout-page/100990
TABLE OF CONTENT:
1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
4. Key Insights
4.1 Prevalence of Key Disease Associated with the Scope - U.S., 2018
4.2 New Product Launch
4.3 Pipeline Analysis
4.4 Regulatory Scenario
4.5. Reimbursement Scenario
4.6. Patent Snapshot of Biologics
4.6 Key Industry Developments - Partnerships, Mergers & Acquisitions
More Trending Topics from Future Business Insights-
Telehealth Market Is Expected to overtake US$ 266.8 Bn by 2026, at a CAGR Of 23.4%
Corn Starch Market 2019 Global Industry Size, Segments, Applications and Growth Factor Analysis Research Report 2026
Contact Info:
Name: Mr. Ashwin Arora
Email: Send Email
Organization: Fortune Business Insights Pvt. Ltd.
Website: https://www.fortunebusinessinsights.com/
Release ID: 88908643